Eisai Co., Ltd.

4523.T

TSEBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 31, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
Perampanel	Phase 3	Partial-onset Seizures	-
E0302 (mecobalamin)	Phase 3	Amyotrophic Lateral Sclerosis (ALS)	-
Rufinamide	Phase 3	Lennox-Gastaut Syndrome	-
Lemborexant	Phase 3	Sleep Initiation and Maintenance Disorders	-
Teprenone	Phase 3	Gastric or Duodenal Ulcers Caused by Low-dose Aspirin	-
T-614	Phase 3	Rheumatoid Arthritis	-
Placebo	Phase 3	Non-erosive Gastroesophageal Reflux Disease	-
Eszopiclone 1 mg	Phase 3	Primary Insomnia	-
Eperisone hydrochloride and Diclofenac sodium	Phase 3	Acute Musculoskeletal Spasm Due to Low Back Pain	-
Clevudine	Phase 3	Chronic Hepatitis B	-
Rabeprazole	Phase 3	Gastroesophageal Reflux Disease	-
Eszopiclone 1 mg- Elderly	Phase 3	Insomnia	-
E3810	Phase 3	Refractory Reflux Esophagitis	-
Donepezil 5 mg	Phase 3	Dementia With Lewy Bodies (DLB)	-
methylcobalamin	Phase 3	Amyotrophic Lateral Sclerosis	-
E2020	Phase 3	Alzheimer's Type Dementia	-
E7389 (Eribulin Mesylate)	Phase 3	HER2-Negative Breast Cancer	-
menatetranone	Phase 3	Postmenopausal Osteoporosis	-
Dotinurad	Phase 3	Gout	-
E2007	Phase 2	Epilepsy	-
E6742	Phase 2	Lupus Erythematosus, Systemic	-
E7389-LF	Phase 2	Solid Neoplasms	-
E2020-Donepezil hydrochloride	Phase 2	Down Syndrome	-
avatrombopag	Phase 2	Thrombocytopenia Associated With Chronic Liver Disease	-
3 mg Donepezil hydrochloride	Phase 2	Dementia With Lewy Bodies (DLB)	-
E7777	Phase 2	Peripheral T-cell Lymphoma	-
E7080 capsule	Phase 2	Thyroid Cancer	-
Lenvatinib	Phase 2	Biliary Tract Cancer	-
Rabeprazole sodium, 5 mg Tablets	Phase 2	Healthy	-
Tazemetostat	Phase 2	Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma	-
E6011	Phase 2	Rheumatoid Arthritis	-
E7090	Phase 2	Cholangiocarcinoma	-
eribulin mesylate	Phase 2	Soft Tissue Sarcoma	-
E5555	Phase 2	Acute Coronary Syndrome	-
BOTULINUM TOXIN TYPE B	Phase 2	Cervical Dystonia	-
E5555 50 mg	Phase 2	Coronary Artery Disease	-

Catalyst Timeline

2 upcoming, 0 past

Phase 2Next

E7389-LF Phase 2 Results Expected

Mar 31, 2026E7389-LF

Primary completion for E7389-LF trial (NCT04078295) in Solid Neoplasms

Source

Phase 2

E7090 Phase 2 Results Expected

Mar 31, 2026E7090

Primary completion for E7090 trial (NCT04238715) in Cholangiocarcinoma

Source

Regulatory Approvals

4523.T News

Eisai Co., Ltd.

4523.T

TSEBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 31, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
Perampanel	Phase 3	Partial-onset Seizures	-
E0302 (mecobalamin)	Phase 3	Amyotrophic Lateral Sclerosis (ALS)	-
Rufinamide	Phase 3	Lennox-Gastaut Syndrome	-
Lemborexant	Phase 3	Sleep Initiation and Maintenance Disorders	-
Teprenone	Phase 3	Gastric or Duodenal Ulcers Caused by Low-dose Aspirin	-
T-614	Phase 3	Rheumatoid Arthritis	-
Placebo	Phase 3	Non-erosive Gastroesophageal Reflux Disease	-
Eszopiclone 1 mg	Phase 3	Primary Insomnia	-
Eperisone hydrochloride and Diclofenac sodium	Phase 3	Acute Musculoskeletal Spasm Due to Low Back Pain	-
Clevudine	Phase 3	Chronic Hepatitis B	-
Rabeprazole	Phase 3	Gastroesophageal Reflux Disease	-
Eszopiclone 1 mg- Elderly	Phase 3	Insomnia	-
E3810	Phase 3	Refractory Reflux Esophagitis	-
Donepezil 5 mg	Phase 3	Dementia With Lewy Bodies (DLB)	-
methylcobalamin	Phase 3	Amyotrophic Lateral Sclerosis	-
E2020	Phase 3	Alzheimer's Type Dementia	-
E7389 (Eribulin Mesylate)	Phase 3	HER2-Negative Breast Cancer	-
menatetranone	Phase 3	Postmenopausal Osteoporosis	-
Dotinurad	Phase 3	Gout	-
E2007	Phase 2	Epilepsy	-
E6742	Phase 2	Lupus Erythematosus, Systemic	-
E7389-LF	Phase 2	Solid Neoplasms	-
E2020-Donepezil hydrochloride	Phase 2	Down Syndrome	-
avatrombopag	Phase 2	Thrombocytopenia Associated With Chronic Liver Disease	-
3 mg Donepezil hydrochloride	Phase 2	Dementia With Lewy Bodies (DLB)	-
E7777	Phase 2	Peripheral T-cell Lymphoma	-
E7080 capsule	Phase 2	Thyroid Cancer	-
Lenvatinib	Phase 2	Biliary Tract Cancer	-
Rabeprazole sodium, 5 mg Tablets	Phase 2	Healthy	-
Tazemetostat	Phase 2	Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma	-
E6011	Phase 2	Rheumatoid Arthritis	-
E7090	Phase 2	Cholangiocarcinoma	-
eribulin mesylate	Phase 2	Soft Tissue Sarcoma	-
E5555	Phase 2	Acute Coronary Syndrome	-
BOTULINUM TOXIN TYPE B	Phase 2	Cervical Dystonia	-
E5555 50 mg	Phase 2	Coronary Artery Disease	-

Catalyst Timeline

2 upcoming, 0 past

Phase 2Next

E7389-LF Phase 2 Results Expected

Mar 31, 2026E7389-LF

Primary completion for E7389-LF trial (NCT04078295) in Solid Neoplasms

Source

Phase 2

E7090 Phase 2 Results Expected

Mar 31, 2026E7090

Primary completion for E7090 trial (NCT04238715) in Cholangiocarcinoma

Source

Regulatory Approvals

4523.T News